Analyst Ratings For Allogene Therapeutics Inc (NASDAQ:ALLO)
Today, JPMorgan Chase & Co. initiated coverage on Allogene Therapeutics Inc (NASDAQ:ALLO) with a Neutral.
There are 2 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Allogene Therapeutics Inc (NASDAQ:ALLO) is Buy with a consensus target price of N/A per share, a potential N/A.
Some recent analyst ratings include
- 11/5/2018-Allogene Therapeutics Inc (NASDAQ:ALLO) has coverage initiated with a Neutral rating
- 11/5/2018-Allogene Therapeutics Inc (NASDAQ:ALLO) has coverage initiated with a Buy rating
- 11/5/2018-Allogene Therapeutics Inc (NASDAQ:ALLO) has coverage initiated with a Buy rating
Recent Trading Activity for Allogene Therapeutics Inc (NASDAQ:ALLO)
Shares of Allogene Therapeutics Inc closed the previous trading session at 27,69 +0,74 2,75 % with 27.32 shares trading hands.